xortx.com (XRTX) - Market Value to Book Value Ratio
XORTX Therapeutics Inc. (XRTX) assets are not subject to the influence of GDP or seasonality, ensuring high macro-resilience. The company's market-to-book ratio exhibits volatility, with the metric currently standing at 0.33. Current stability relies on attracting investment due to the absence of regular revenue, while long-term growth is based on the patent protection of unique formulas for kidney therapy.
XORTX Therapeutics Inc (XRTX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- debt obligations and liquidity statistics:
- earnings and valuation multiples indicators:
Basic company analysis:XORTX Therapeutics Inc. - XRTX
Long-term asset screening requires a synthesis of market quotes and financial statements. This indicator compares a company's market value with its net assets to determine the extent of capital overvaluation or undervaluation. For XORTX Therapeutics Inc. (XRTX), which is developing innovative drugs for kidney diseases, this gap reflects market expectations for future breakthroughs. An investor can track the dynamics of business prospects via the price-to-book ratio.
Competitor analysis
ARGX (argenx SE) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio BNTX|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|Market Cap to Net Assets Ratio IMNM|Market Capitalization to Book Value Ratio Gossamer Bio Corp.|Market Value to Book Value Ratio KalVista Pharmaceuticals (KALV)|septerna.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Market-to-Book Ratio|RIGL: Market Cap to Net Assets Ratio|ANAB (AnaptysBio Inc.) - Capitalization to Book Value Ratio|Astria Therapeutics (ATXS) - Market Value to Book Value Ratio|Market-to-Book Ratio engene.com (ENGN)|Market Value to Book Value Ratio RAPT Therapeutics|JBIO: Market Value to Book Value|Market Cap to Net Assets Ratio ACRS (Aclaris)|Market Cap to Book Value Multiple KYTX|Tiziana Life Sciences - Market Cap to Net Assets Ratio|CABA: Capitalization to Book Value Ratio|VTYX: Market Cap to Net Assets Ratio|Market Value to Book Value THTX (Theratechnologies, Inc.)|AVTX (Avalo Therapeutics Inc.) - Market Cap to Net Assets Ratio|ELDN: Market Cap to Book Value Multiple|AGEN (Agenus) - Market Capitalization to Book Value Ratio|CLYM: Market Value to Book Value|Market Capitalization to Book Value Ratio ZURA|ATYR - Market-to-Book Ratio|Market Value to Book Value Ratio Adagene Inc. ADAG|Market Value to Book Value IMA|Shattuck Therapeutics - Market Capitalization to Book Value Ratio|EQ - Market Capitalization to Book Value Ratio|connectbiopharm.com (CNTB) - Market Value to Book Value Ratio|Market Capitalization to Net Assets IMUX (Immunic)|ATRA (Atara Biotherapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio InflaRx GmbH IFRX|Market Cap to Net Assets Ratio XFOR (X4 Pharmaceuticals)|Market Capitalization to Book Value Ratio adicetbio.com (ACET)|Celularity - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple INMB (INmune Bio Inc)|Barinthus Bio - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Kezar Life Sciences Inc KZR|SABS: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio akaritx.com|Market Value to Book Value Ratio Enlivex Therapeutics Ltd|Q32 Bio Corp (QTTB) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio GOVX (GeoVax Labs Inc)|EDSA (Edesa Biotech Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio IBIO (iBio, Inc.)|Market Capitalization to Book Value Carisma Therapeutics Inc (CARM)|XTLB - Market Value to Book Value Ratio|BOLT (Bolt Biotherapeutics) - Capitalization to Book Value Ratio|HCWB: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Aptevo Therapeutics Inc.|Market Cap to Net Assets Ratio AIM|Aditxt Corp (ADTX) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio GRI (GRI Bio)|Vyome Holdings Inc. - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Revelation Bio REVB|Market Value to Book Value INDP|SCNI: Market Cap to Net Assets Ratio|CalciMedica, Inc. - Market Cap to Book Value Multiple|AFMD (affimed.com) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio ALLK|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|IGM Bio - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio ITOS|OCEA (oceanbiomedical.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|Market Capitalization to Book Value Ratio Third Harmonic Bio Inc. THRD